FOSPHENYTOIN SODIUM Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Fosphenytoin Sodium, and when can generic versions of Fosphenytoin Sodium launch?
Fosphenytoin Sodium is a drug marketed by Am Regent, Amneal, Apotex Inc, Dr Reddys, Fresenius Kabi Usa, Gland Pharma Ltd, Hikma, Hikma Farmaceutica, Hospira, Norvium Bioscience, Sun Pharm, and Wockhardt. and is included in fourteen NDAs.
The generic ingredient in FOSPHENYTOIN SODIUM is fosphenytoin sodium. There are eight drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the fosphenytoin sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Fosphenytoin Sodium
A generic version of FOSPHENYTOIN SODIUM was approved as fosphenytoin sodium by FRESENIUS KABI USA on August 6th, 2007.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for FOSPHENYTOIN SODIUM?
- What are the global sales for FOSPHENYTOIN SODIUM?
- What is Average Wholesale Price for FOSPHENYTOIN SODIUM?
Summary for FOSPHENYTOIN SODIUM
US Patents: | 0 |
Applicants: | 12 |
NDAs: | 14 |
Finished Product Suppliers / Packagers: | 6 |
Raw Ingredient (Bulk) Api Vendors: | 61 |
Clinical Trials: | 3 |
Patent Applications: | 830 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for FOSPHENYTOIN SODIUM |
DailyMed Link: | FOSPHENYTOIN SODIUM at DailyMed |
Recent Clinical Trials for FOSPHENYTOIN SODIUM
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Nobelpharma | Phase 3 |
Shaheed Zulfiqar Ali Bhutto Medical University | N/A |
Institute of Medical Sciences of the Banaras Hindu University (BHU),India | Phase 2 |